Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 + Enlonstobart vs Anti-PD-(L)-1 in Adjuvant Stage II-IIIB NSCLC
NCT07672223Phase 3Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Sep 2029
01
Overview
A Phase 3 trial of CPO301 in non-small cell lung cancer (NSCLC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07672223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672223.